Chitooligosaccharides Improve the Efficacy of Checkpoint Inhibitors in a Mouse Model of Lung Cancer
- Supplementary File 1:
ZIP-Document (ZIP, 4773 KiB)
Johansen, A.Z.; Carretta, M.; Thorseth, M.-L.; Khan, S.; Fjæstad, K.Y.; Brøchner, C.B.; Linder, H.; Ankjærgaard, C.; Donia, M.; Chen, I.; Nielsen, D.L.; Behrens, C.P.; Madsen, D.H. Chitooligosaccharides Improve the Efficacy of Checkpoint Inhibitors in a Mouse Model of Lung Cancer. Pharmaceutics 2022, 14, 1046. https://doi.org/10.3390/pharmaceutics14051046
Johansen AZ, Carretta M, Thorseth M-L, Khan S, Fjæstad KY, Brøchner CB, Linder H, Ankjærgaard C, Donia M, Chen I, Nielsen DL, Behrens CP, Madsen DH. Chitooligosaccharides Improve the Efficacy of Checkpoint Inhibitors in a Mouse Model of Lung Cancer. Pharmaceutics. 2022; 14(5):1046. https://doi.org/10.3390/pharmaceutics14051046
Chicago/Turabian StyleJohansen, Astrid Z., Marco Carretta, Marie-Louise Thorseth, Shawez Khan, Klaire Y. Fjæstad, Christian B. Brøchner, Hannes Linder, Christina Ankjærgaard, Marco Donia, Inna Chen, Dorte L. Nielsen, Claus P. Behrens, and Daniel H. Madsen. 2022. "Chitooligosaccharides Improve the Efficacy of Checkpoint Inhibitors in a Mouse Model of Lung Cancer" Pharmaceutics 14, no. 5: 1046. https://doi.org/10.3390/pharmaceutics14051046